Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 110 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant Clear all
Completed Not applicable Interventional

Rosiglitazone and Exercise Training: Effects on HIV-Infected People With Insulin Resistance, Hypertriglyceridemia, and Adipose Tissue Maldistribution

NCT00025753
View directory record Official record
Conditions
HIV Infections, Insulin Resistance
Interventions
rosiglitazone (Avandia), Aerobic and weight lifting exercise training
Drug · Behavioral
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional Results available

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

NCT00612066
View directory record Official record
Conditions
Cushing's Disease
Interventions
rosiglitazone maleate
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 1 Interventional

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

NCT01100619
View directory record Official record
Conditions
Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma
Interventions
rosiglitazone, XL184
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
5
States / cities
Duarte, California • Boston, Massachusetts • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Rosiglitazone Effect on Mitochondria and Lipoatrophy

NCT00367744
View directory record Official record
Conditions
HIV Infections
Interventions
Rosiglitazone, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 1 Interventional

The Impact of Obesity and Obesity Treatments on Breast Cancer

NCT00933309
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Avandamet
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients

NCT00123643
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rosiglitazone, glyburide
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
25 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects

NCT00615212
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK376501, Midazolam, Rosiglitazone, Flurbiprofen
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Use of Rosiglitazone to Treat Asthma

NCT00614874
View directory record Official record
Conditions
Asthma
Interventions
rosiglitazone
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 1 Interventional

Endothelial Dysfunction as a Risk Factor in HIV Study

NCT00039663
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin, Gemfibrozil, Rosiglitazone
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Gene Regulation by Thiazolidinediones

NCT00567593
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Rosiglitazone
Drug
Lead sponsor
James Lewis
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 2 Interventional

Rosiglitazone in the Treatment of HIV-Associated Hyperlipidemia

NCT00006493
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
Rosiglitazone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 4 Interventional

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

NCT00672919
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

NCT00099918
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Not applicable Interventional Results available

Preferred Treatment of Type 1.5 Diabetes

NCT00194896
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
rosiglitazone, glyburide
Drug
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 69 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

NCT00381238
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Sun City, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 10, 2026, 6:54 PM EDT
Terminated Not applicable Interventional

Rosiglitazone-Induced Weight Gain

NCT00225225
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rosiglitazone, dietary recommendation for weight maintenance
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Oct 10, 2026, 6:54 PM EDT
Completed No phase listed Observational

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

NCT03492580
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
714,582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 1 Interventional

Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)

NCT00193648
View directory record Official record
Conditions
Focal Glomerulosclerosis
Interventions
Rosiglitazone (Avandia), Adalimumab (Humira)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
2 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
New Hyde Park, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2007 · Synced Oct 10, 2026, 6:54 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers

NCT00490568
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone XR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
51 Years to 91 Years
Enrollment
1,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
41
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance

NCT00130286
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X, Body Weight Changes
Interventions
Rosiglitazone, Recombinant human growth hormone + rosiglitazone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

NCT00265148
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
9
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 10, 2026, 6:54 PM EDT
Completed Phase 2 Interventional

Insulin, Neurogenetics and Memory in Alzheimer's Disease

NCT00018382
View directory record Official record
Conditions
Alzheimer Disease
Interventions
rosiglitazone
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
55 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 10, 2026, 6:54 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT00252499
View directory record Official record
Conditions
Fatty Liver, Insulin Resistance
Interventions
rosiglitazone, fenofibrate, placebo for rosiglitazone, placebo for fenofibrate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 10, 2026, 6:54 PM EDT
Not listed Phase 2 Interventional

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

NCT00098852
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
rosiglitazone maleate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 10, 2026, 6:54 PM EDT